Ronald Goldwater
Overview
Explore the profile of Ronald Goldwater including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sullivan-Bolyai J, Allen L, Cannon R, Cohane K, Dunzo E, Goldwater R, et al.
J Infect Dis
. 2024 Nov;
PMID: 39570031
Background: Diphtheria is a recurrent threat with endemic still occurs in many parts of the world. The standard of care is horse serum-derived diphtheria antitoxin (eDAT), which is in critical...
2.
Friedrichsen M, Endahl L, Kreiner F, Goldwater R, Kankam M, Toubro S, et al.
Mol Metab
. 2024 Sep;
89:102023.
PMID: 39245214
No abstract available.
3.
Friedrichsen M, Endahl L, Kreiner F, Goldwater R, Kankam M, Toubro S, et al.
Mol Metab
. 2023 Sep;
78:101801.
PMID: 37690519
Objective: Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from three phase 1 trials investigating the safety, tolerability,...
4.
Cohen-Rabbie S, Mattinson A, So K, Wang N, Goldwater R
Clin Ther
. 2022 Apr;
44(4):565-576.
PMID: 35410754
Purpose: Selumetinib (ARRY-142886) is an oral, potent, and highly selective allosteric mitogen-activated protein kinase kinase 1/2 inhibitor approved for the treatment of pediatric patients (≥2 years of age) with neurofibromatosis...
5.
Cohen-Rabbie S, Mattinson A, So K, Wang N, Goldwater R
Clin Transl Sci
. 2022 Feb;
15(4):878-888.
PMID: 35170228
Selumetinib is an oral, potent, and highly selective allosteric MEK1/2 inhibitor approved for the treatment of pediatric patients (aged ≥2 years) with neurofibromatosis type 1 who have symptomatic, inoperable plexiform...
6.
Ito M, Spence A, Blauwet M, Heo N, Goldwater R, Maruff P, et al.
J Psychopharmacol
. 2022 Jan;
36(6):756-767.
PMID: 34994232
Background: ASP8062 is a novel orally active GABA receptor positive allosteric modulator in clinical development for the treatment of alcohol use disorder (AUD) and opioid use disorder (OUD). Aims: This...
7.
Ren S, Vishwanathan K, Cantarini M, Frewer P, Hara I, Scarfe G, et al.
Br J Clin Pharmacol
. 2021 Jul;
88(2):655-668.
PMID: 34322894
Aims: We investigated savolitinib pharmacokinetics (PK) when administered alone or in combination with rifampicin, itraconazole or famotidine, and investigated midazolam PK when administered with or without savolitinib in healthy males....
8.
Desai A, Helmick M, Heo N, Moy S, Stanhope S, Goldwater R, et al.
Antimicrob Agents Chemother
. 2021 Jun;
65(9):e0044221.
PMID: 34181478
For critically ill patients with invasive fungal infections, a nasogastric (NG) tube can be an alternative route for administration of isavuconazonium sulfate (ISAVUSULF). This was a randomized, open-label, 2-period, 2-sequence...
9.
Sahota T, Dota C, Vik T, Yan W, Verheijen R, Walker S, et al.
Clin Pharmacol Drug Dev
. 2021 Jan;
10(5):521-534.
PMID: 33400845
Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, bioavailable, selective MET-tyrosine kinase inhibitor. This randomized, double-blind, 3-way, crossover phase 1 study of savolitinib versus moxifloxacin (positive control) and placebo-evaluated effects on...
10.
Stack A, Han D, Goldwater R, Johansson S, Dronamraju N, Oscarsson J, et al.
J Clin Endocrinol Metab
. 2020 Oct;
106(5):e2347-e2356.
PMID: 33075806
Context: Combining a sodium-glucose cotransporter 2 inhibitor with a xanthine oxidase inhibitor (XOI) and a urate transporter 1 (URAT1) inhibitor may enhance serum uric acid (sUA) lowering. However, concerns exist...